US Al in Pathology Market (2024-2029)
The US Al in Pathology Market was valued at $15.63 Million in 2024 and projected to reach to $60.03 Million by 2029, representing a compound annual growth rate of CAGR 25.7%. The US AI in Pathology Market is positioned for exceptional growth through 2029, driven by healthcare providers' urgent need to address pathologist shortages and increase diagnostic throughput.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
US Al in Pathology Market Trends and Insights
- This robust growth trajectory reflects the US healthcare sector's accelerating adoption of artificial intelligence technologies to enhance diagnostic accuracy and operational efficiency in pathology laboratories.
- The US market is driven by increasing demand for automated image analysis, digital pathology solutions, and AI-powered diagnostic tools that improve turnaround times and reduce human error in tissue and specimen analysis. Key factors propelling the US market include substantial investments in healthcare IT infrastructure, favorable regulatory frameworks, and the presence of leading AI and diagnostic companies.
- The US pathology market benefits from high healthcare spending, advanced laboratory networks, and strong clinical adoption rates among major medical institutions.
- Between 2024 and 2029, the US is expected to consolidate its position as a global leader in AI pathology innovation, with widespread integration across academic medical centers, hospital systems, and independent diagnostic laboratories..
Key Market Statistics
- CAGR (2024-2029) CAGR 25.7%
- Market Size, 2024 ~USD 15.63 Million
- Forecast, 2029 ~USD 60.03 Million
- Country US
US Al in Pathology Market Overview
Market Valuation Growth :
The US AI in Pathology Market is valued at $15.63 million in 2024 and is projected to reach $60.03 million by 2029, representing a compound annual growth rate of 25.7%.
Healthcare Technology Adoption :
US healthcare providers are rapidly integrating AI solutions into pathology workflows to improve diagnostic accuracy, reduce turnaround times, and enhance laboratory operational efficiency across major medical institutions.
Regulatory Environment :
The US market benefits from established FDA approval pathways for AI-powered diagnostic tools, creating a structured framework that accelerates innovation while maintaining quality standards in pathology applications.
Investment and Innovation :
Significant venture capital and healthcare IT investments are flowing into US-based AI pathology startups and established medical device companies, driving technological advancement and competitive market dynamics.
US Al in Pathology Market Dynamics
- Major US hospitals and laboratory networks are increasingly deploying AI-powered image analysis, digital pathology platforms, and automated screening tools to enhance clinical outcomes.
- Regulatory clarity from the FDA and reimbursement pathway development are expected to accelerate adoption rates among US healthcare systems.
- The convergence of digital pathology infrastructure investments and AI capability maturation creates a compelling market opportunity for vendors and healthcare organizations seeking competitive advantages in diagnostic precision and operational cost reduction..
Related Ecosystem
Healthcare It
- Computed Tomography (CT)
- Machine Learning
- Magnetic Resonance Imaging (MRI)
- Natural Language Processing (NLP)
- Predictive Analytics
- CERNER CORPORATION
- PHILIPS HEALTHCARE
- Oracle Corporation
- GE HealthCare Technologies Inc.
- Siemens healthineers
Key Takeaways
- The US AI in Pathology Market is valued at $15.63 million in 2024 and is forecast to grow to $60.03 million by 2029, representing a 25.7% CAGR.
- The US market is driven by high healthcare expenditure, advanced digital infrastructure, and strong adoption of AI-powered diagnostic solutions across major medical institutions.
- Regulatory support and the presence of leading technology and healthcare companies position the US as a global innovation hub for AI pathology applications.
- The US pathology sector is increasingly integrating AI for automated image analysis, specimen processing, and diagnostic accuracy improvement through 2029.
Al in Pathology Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | IMAGE ANALYSIS (Function) |
| Forecast Period | 2024-2029 |
| Growth Rate | CAGR of 26.5% from 2024 to 2029 |
| Largest Segment | CONVOLUTIONAL NEURAL NETWORKS (CNNS) (Neural Network) |
| Market Size Base Year (Billions) | ~USD 0.08 (2024) |
| Revenue Forecast (Billions) | ~USD 0.347 (2029) |
| Segments Covered | Offering, Type, Neural Network, Function, Use Case, End User |
US Al in Pathology Market Report Segmentation
6 segment dimensions are covered across the global market.
By Offering
- End-To-End Solutions
- Hardware
- Niche Point Solutions
- Technology
By Type
- Candidate Selection
- Hit Identification & Prioritization
- Hit-To-Lead Identification
- Lead Optimization
- Microscope
- Scanners
- Storage Systems
- Target Identification & Selection
- Target Validation
By Neural Network
- Convolutional Neural Networks (Cnns)
- Generative Adversarial Networks (Gans)
- Other Neural Networks
- Recurrent Neural Networks (Rnns)
By Function
- Automated Report Generation
- Cdss
- Data Management
- Diagnostics
- Image Analysis
- Predictive Analytics
- Quality Assurance Tools
- Workflow Management
By Use Case
- Clinical Workflow
- Disease Diagnosis & Prognosis
- Drug Discovery
- Training & Education
By End User
- Academic & Research Institutes
- Hospitals & Reference Laboratories
- Pharmaceutical & Biopharmaceutical Companies
US: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 3.2 | 3.8 | 4.5 | 5.4 | 6.6 | 8.1 | 10 | 12.4 | 22.4 |
| HOSPITALS & REFERENCE LABORATORIES | 10.4 | 12.5 | 15.2 | 18.7 | 23.1 | 28.8 | 36.1 | 45.5 | 24.6 |
| PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES | 12.8 | 15.5 | 19.1 | 23.9 | 30 | 37.9 | 48.2 | 61.7 | 26.4 |
| TOTAL | 26.4 | 31.8 | 38.8 | 48 | 59.8 | 74.9 | 94.3 | 119.6 | 25.3 |
Target Audience
- Healthcare IT Vendors : AI and digital pathology solution providers need US market sizing and growth forecasts to prioritize product development investments, allocate sales resources, and establish realistic revenue targets in this high-growth segment.
- Hospital & Laboratory Networks : US healthcare systems and independent pathology labs require market intelligence to justify AI technology investments, benchmark adoption rates against peers, and evaluate vendor solutions within the competitive landscape.
- Investment & Private Equity Firms : Investors evaluating healthcare IT opportunities need validated US market data to assess portfolio company growth potential, identify acquisition targets, and make informed capital allocation decisions in the pathology AI space.
- Medical Device Manufacturers : Established diagnostic equipment and imaging companies need US market forecasts to guide strategic pivots toward AI-integrated solutions and understand market timing for product launches and feature enhancements.
- Healthcare Consultants & Analysts : Management consulting firms and research analysts require authoritative US market data to support client advisory work, publish industry reports, and provide evidence-based recommendations on pathology technology adoption.
Reasons to Buy this Report
- Market Size & Growth Validation : Quantified US market data with precise valuations ($15.63M in 2024, $60.03M in 2029) and verified 25.7% CAGR enables confident investment decisions and strategic planning for US market entry or expansion.
- Competitive Intelligence : Gain insights into US-specific market dynamics, regulatory landscape, and competitive positioning to identify white space opportunities and benchmark performance against regional competitors in the pathology AI sector.
- Strategic Planning & Forecasting : Leverage detailed US market projections through 2029 to inform product development roadmaps, sales strategies, and resource allocation decisions tailored to the American healthcare market's unique requirements.
- Stakeholder Communication : Access credible, data-backed market intelligence to support investor pitches, board presentations, and partnership negotiations with US healthcare systems, venture firms, and medical technology companies.
- Risk Mitigation : Understand US market maturity, adoption barriers, and growth catalysts to anticipate challenges, identify regulatory considerations, and develop contingency strategies for successful market penetration.
Frequently asked questions
What is the current size of the US AI in Pathology Market?
The US AI in Pathology Market was valued at $15.63 million in 2024 and is expected to reach $60.03 million by 2029.
What is the projected growth rate for the US AI in Pathology Market?
The US AI in Pathology Market is projected to grow at a compound annual growth rate (CAGR) of 25.7% from 2024 to 2029.
What are the primary drivers of growth in the US AI in Pathology Market?
Key drivers include increased healthcare IT investments, favorable regulatory environments, high clinical adoption rates, and demand for automated diagnostic solutions in US pathology laboratories.
Which segments are leading the US AI in Pathology Market?
Digital pathology, automated image analysis, and AI-powered diagnostic tools are among the leading segments driving growth in the US market.
How is the US positioned in the global AI in Pathology Market?
The US is a global leader in AI pathology innovation, supported by advanced healthcare infrastructure, substantial R&D investments, and widespread adoption across major medical institutions.
RESEARCH METHODOLOGY
This research study involved the extensive use of primary and secondary sources. It analyzes various factors affecting the industry to identify the segmentation, industry trends, key players, the competitive landscape, and key market dynamics.
Secondary Research
This research study involved the wide use of secondary sources, directories, databases such as Dun & Bradstreet, Bloomberg Businessweek, and Factiva, whitepapers, annual reports, and companies’ house documents. Secondary research was undertaken to identify and collect information for this extensive, technical, market-oriented, and commercial study of the AI in pathology market. It was also used to obtain important information about the top players, market classification, and segmentation according to industry trends to the bottom-most level, geographic markets, and key developments related to the market. A database of the key industry leaders was also prepared using secondary research.
Primary Research
In the primary research process, various supply-side and demand-side sources were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side included industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, engineers, and related key executives from various companies and organizations operating in the AI in pathology market. Primary sources from the demand side included personnel from pharmaceutical & biopharmaceutical companies, research institutes, and hospitals (small, medium-sized, and large hospitals).
A breakdown of the primary respondents is provided below:
Note 1: C-level primaries include CEOs, CFOs, COOs, and VPs.
Note 2: Other designations include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.
Note 3: Companies are classified into tiers based on their total revenue. As of 2024, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = < USD 1.00 billion.
Source: MarketsandMarkets Analysis
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The total size of the AI in pathology market was determined after data triangulation through the two approaches mentioned below. After the completion of each approach, the weighted average of these approaches was taken based on the level of assumptions used in each approach.
Data Triangulation
The size of the AI in pathology market was estimated through segmental extrapolation using the bottom-up approach. The methodology used is as given below:
- Revenues for individual companies were gathered from public sources and databases.
- Shares of leading players were gathered from secondary sources to the extent available. In certain cases, shares of AI in pathology businesses have been ascertained after a detailed analysis of various parameters, including product portfolios, market positioning, selling price, and geographic reach & strength.
- Individual shares or revenue estimates were validated through interviews with experts.
- The total revenue in the AI in pathology market was determined by extrapolating the market share data of major companies.
Market Definition
The AI in pathology market refers to the commercial space where companies develop, market, and provide products and services that incorporate artificial intelligence technologies specifically designed for pathology applications. This market leverages AI algorithms, machine learning techniques, and advanced computational tools to enhance and automate various aspects of the pathology workflow.
Stakeholders
- Pathologists
- Suppliers and Distributors of Digital Pathology Equipment
- AI System and Solution Providers
- Medical Research and Biopharmaceutical Companies
- Pharmaceutical Companies and CROs
- Hospitals and Clinics
- Laboratories
- Regulatory Bodies
- Academic and Medical Research Institutes
- Universities and Research Organizations
- Forums, Alliances, and Associations
- Technology Providers
- Healthcare Payers
Report Objectives
- To define, describe, and forecast the AI in pathology market by offering, neural network, function, use case, end user, and region
- To provide detailed information about the major factors influencing the market growth (drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market segments in North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile key players and comprehensively analyze their market shares and core competencies in the AI in pathology market
- To benchmark players operating in the AI in pathology market using the Competitive Leadership Mapping framework, which analyzes key market players and start-ups on various parameters within the broad categories of market share/rank and product/service footprint
- To track and analyze competitive developments such as product launches, expansions, agreements, partnerships, collaborations, product approvals, investments, and acquisitions to strengthen their market presence in the AI in pathology market.
Get the Full AI in Pathology Market Report
Full forecast, segment splits, and company analysis for all AI in Pathology Market.
- Canada Al in Pathology Market
- UK Al in Pathology Market
- Germany Al in Pathology Market
- France Al in Pathology Market
- Italy Al in Pathology Market
- Spain Al in Pathology Market
- China Al in Pathology Market
- Japan Al in Pathology Market
- India Al in Pathology Market
- Brazil Al in Pathology Market
- Mexico Al in Pathology Market
- Rest Of Europe Al in Pathology Market
- Rest Of Asia Pacific Al in Pathology Market
- Rest Of Latin America Al in Pathology Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
